News for AIKI Stock

CORRECTING and REPLACING DatChat Announces a 1:10 Reverse Stock Split Effective at the Open of Trading on September 20, 2023 DatChat Announces a 1:10 Reverse Stock Split Effective at the Open of Trading on September 19, 2023 DatChat to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 DatChat Files Patent for Access to Secure Group-Based Digital Assets Across its Metaverse and Social Media Platforms DatChat's Habytat Metaverse Enters Marketing Partnership with Cloud Water Brands DatChat Reaches Milestone of Over 75,000 Users on Its AI-Powered Habytat Metaverse DatChat Launches Artificial Intelligence Powered Pets in Its Habytat Virtual World DatChat Publishes Strong Growth Metrics for Its Habytat Metaverse DatChat Receives Notice of Allowance for Secure Web RTC Real Time Communication Service For Audio and Video Streaming Communications DatChat to Present at the Investor, Bizz, Art & Web3 Forum in Bogota, Colombia Dominari Securities CEO, Kyle Wool, Discusses the IPO Market on "The Claman Countdown" DatChat to Showcase Habytat Metaverse at TNW Conference in Amsterdam DatChat, Inc. Provides Update on Share Repurchase Program DatChat Launches the Habytat Mobile Metaverse for the Masses Dominari Holdings Appoints George Way Chief Financial Officer Habytat to Launch AI-Powered Pets in The Metaverse Habytat by SmarterVerse Creates Virtual Wynwood Arts District, Offers 200 Artists Complimentary Gallery Spaces Habytat by SmarterVerse Names Wachsman Communications Agency of Record Dominari Holdings Provides Update on Share Repurchase Program AIkido Pharma Announces Name and Stocker Ticker Symbol Change to Dominari Holdings Inc. (Nasdaq: DOMH) AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes AIkido Share Repurchase Continues AIkido Purchases More Shares Share Repurchase Program Continues AIkido Pharma Continues Share Repurchase Program AIkido Pharma Provides Update on Share Repurchase Program Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer AIkido Pharma Confirms Receipt of Unsolicited Offer AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements AIkido Inc. Announces the Formation of a New Financial Services Subsidiary AIkido Pharma Inc. Appoints New Director, Soo Yu AIkido Announces Reverse Stock Split AIkido Pharma Secures Interest in Databricks Inc. /DISREGARD RELEASE: AIkido Pharma Inc./ AIkido Reports Slinger Bag Inc.'s Filing for Nasdaq Public Listing AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider Discord, Inc. AIkido Pharma Announces Strategic Investment in MasterClass Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment Cedars-Sinai Medical Center and AIkido Pharma Inc. Enter Into Master Collaboration Agreement AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug AIkido Pharma Inc. Announces Closing of $22 Million Registered Direct Offering AIkido Pharma Inc. Announces $22 Million Registered Direct Offering AIkido Pharma Announces Share Repurchase Program AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News AIkido Pharma Reports Filing for Expanded Worldwide Patent Coverage on Key Assets AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc. /C O R R E C T I O N -- AIkido Pharma Inc./ AIkido Pharma Announces Third Quarter Highlights and Corporate Update AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd AIkido Pharma Secures Interest in Growing Tele-health Company AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching AIkido Provides Update on Use of Machine Learning in Drug Development Program Notice of Allowance Issued for Central Nervous System Peptide Technology AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland AIkido Pharma to Attend the Alzheimer's Association International Conference AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591 AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting AIkido Pharma Inc. to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference, and the LD Micro Invitational Conference AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update AIkido Pharma Announces Dr. Rachel Yehuda's Appearance at SXSW AIkido Pharma Announces Inventor and Scientist Dr. Matthew Frieman Joins Scientific Advisory Board AIkido Pharma Announces Withdrawal of S-1 Registration Statement AIkido Pharma Notes Advancement in Radiopharmaceutical Research AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients AIkido Pharma Provides Business Update AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD AIkido Pharma Announces Dr. Matt Frieman's Appearance on This Week in Virology AIkido Pharma Inc. Updates Announcement of Webcast Link for the H.C. Wainwright Global Life Sciences Conference (Virtual Event) AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event) AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19 AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board Aikido Pharma Secures Early Interest in Next Generation Radiotherapy AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC AIkido Pharma Announces Update On Its Use Of Artificial Intelligence AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference) AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License AIkido Pharma Inc. to Present at The LD 500 Virtual Conference Option for Treatment for Coronavirus Extended AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus